News

VIEW ALL

Feldan Therapeutics Announces a Publication in Nature Communications

Feldan Therapeutics honored at the 2019 ANGES QUÉBEC ANNUAL RENDEZ-VOUS

Amgen and Takeda join the Quantum Leap project led by CQDM and Feldan Therapeutics, to improve a novel intracellular delivery technology

New Corporate Identity for Feldan Therapeutics

François-Thomas Michaud recipient of the Visionary Entrepreneur of the Year Award

FELDAN THERAPEUTICS ANNOUNCES ADDITIONAL INVESTMENT IN SERIES A

FELDAN THERAPEUTICS IS PROUD TO SUPPORT THE 2019TH EDITION OF THE ANNUAL CRISPR CONFERENCE

UNIVERSITY OF IOWA AND FELDAN THERAPEUTICS AWARDED GRANT BY THE NATIONAL INSTITUTES OF HEALTH

FELDAN THERAPEUTICS RAISES $12.5 MILLION IN SERIES A FINANCING ROUND

GC LABCELL AND FELDAN THERAPEUTICS ANNOUNCE LICENSE AGREEMENT TO DEVELOP NEXT-GENERATION NK CELLS FOR IMMUNOTHERAPY USING FELDAN SHUTTLE TECHNOLOGY

FELDAN IS ATTENDING BIO INTERNATIONAL CONVENTION, JUNE 4-7 2018 IN BOSTON, USA.

Feldan Therapeutics awarded US Patent for the second generation of its Feldan Shuttle platform

FELDAN AT TIDES 2018

FELDAN THERAPEUTICS AT RESI 2018 (TORONTO)

READ THE LATEST ON FELDAN SHUTTLE TECHNOLOGY

CQDM WILL PARTNER WITH FELDAN TO SUPPORT A $1.2M PROJECT

FELDAN THERAPEUTICS WILL BE ATTENDING THE INNATE KILLER SUMMIT 2018

READ THE LATEST ON FELDAN SHUTTLE TECHNOLOGY

FELDAN THERAPEUTICS AND GREENCROSS LABCELL ANNOUNCE START OF JOINT COLLABORATION

Feldan Therapeutics new web site !

FELDAN THERAPEUTICS ANNOUNCES INSSUANCE OF FIRST PATENT FOR ITS PEPTIDE-BASED PROTEIN DELIVERY TECHNOLOGY, THE FELAN SHUTTLE

Feldan Therapeutics will be attending the BIO International Convention 2017

FELDAN THERAPEUTICS & ELASMOGEN